Microglial Aβ receptors in Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review describing biological mechanisms without new clinical data
PubMed 25149075 · doi:10.1007/s10571-014-0101-6
What was done
This narrative review synthesizes literature on microglial membrane receptors that bind amyloid beta in Alzheimer's disease. The authors categorized these receptors into scavenger receptors (SCARA-1, MARCO, SCARB-1, CD36, RAGE), G protein-coupled receptors (FPR2, CMKLR1), and Toll-like receptors (TLR2, TLR4, CD14) to review their expression, distribution, and functional roles in amyloid beta uptake, clearance, and neuroinflammatory activation.
What was found
The abstract reports no numerical results or quantitative findings. It describes functional classifications qualitatively: SCARA-1 and CMKLR1 participate in amyloid beta uptake; RAGE mediates microglial activation and proinflammatory mediator production; and CD36, CD36/CD47/alpha6beta1-integrin complexes, CD14/TLR2/TLR4, and FPR2 participate in both clearance and inflammatory signaling. MARCO and SCARB-1 also demonstrate amyloid beta binding capability.
Why it matters
Delineating which microglial receptors mediate beneficial clearance versus harmful neuroinflammation clarifies potential molecular targets for Alzheimer's disease therapeutics.
Limits
This is a narrative review with no systematic search methodology, no reported sample size, and no primary human clinical data. The mechanistic findings summarized from preclinical models may not directly reflect in vivo therapeutic responses in human Alzheimer's disease.
Cited by
- supports Beta-amyloid and phosphorylated tau bind to RAGE (receptor for advanced glycation end products) on microglial cell surfaces.